Valerio Therapeutics (FRA:C4X) EBIT per Share : €-0.16 (TTM As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Valerio Therapeutics EBIT per Share?

Valerio Therapeutics's EBIT per Share for the six months ended in Dec. 2023 was €-0.06. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.16.

During the past 3 years, the average EBIT per Share Growth Rate was -8.80% per year. During the past 5 years, the average EBIT per Share Growth Rate was 11.30% per year. During the past 10 years, the average EBIT per Share Growth Rate was 9.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Valerio Therapeutics's EBIT per Share or its related term are showing as below:

FRA:C4X' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -342.5 Med: 15.2 Max: 73.9
Current: -8.8

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Valerio Therapeutics was 73.90% per year. The lowest was -342.50% per year. And the median was 15.20% per year.

FRA:C4X's 3-Year EBIT Growth Rate is ranked worse than
65.02% of 1278 companies
in the Biotechnology industry
Industry Median: 3.6 vs FRA:C4X: -8.80

Valerio Therapeutics's EBIT for the six months ended in Dec. 2023 was €-8.59 Mil.

Valerio Therapeutics EBIT per Share Historical Data

The historical data trend for Valerio Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valerio Therapeutics EBIT per Share Chart

Valerio Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-0.49

0.04

-0.05

-0.15

-0.14

Valerio Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT per Share	Get a 7-Day Free Trial															-0.01	-0.09	-0.07	-0.10	-0.06

Valerio Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Valerio Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-20.187	/	142.075
=	-0.14

Valerio Therapeutics's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-8.585	/	154.226
=	-0.06

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.16

Valerio Therapeutics (FRA:C4X) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Valerio Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Valerio Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Valerio Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valerio Therapeutics (FRA:C4X) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

ALVIO:France

Address

49 Boulevard du General, Martial Valin, Paris, FRA, 75015

Website

https://www.valeriotx.com

Valerio Therapeutics is a clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA repair functions. Its therapeutic strategy focuses on fighting tumor resistance to treatments, which poses ever-greater therapeutic challenges, especially in aggressive or rare cancers. its approach is based upon unique mechanisms of action on DNA Damage Response. The company focuses on bringing first-in-class and disruptive compounds from preclinical research to proof-of-concept in man in cancer indications with high unmet needs.

Valerio Therapeutics Headlines

No Headlines